Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) announced inducement equity awards granted February 2, 2026, to three newly hired employees.

The company granted 205,000 RSUs and 168,000 stock options under its Inducement Plan, with options priced at $4.19 per share and standard time-based vesting schedules.

The awards were approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Figures

RSU grants: 205,000 RSUs Stock options granted: 168,000 options New employees: 3 employees +5 more

8 metrics

RSU grants 205,000 RSUs Inducement awards to three new employees

Stock options granted 168,000 options Inducement awards to three new employees

New employees 3 employees Recipients of inducement equity grants

Option exercise price $4.19 per share Equal to closing price on grant date

Initial option vesting 25% Vests on first anniversary of grant date

Ongoing option vesting 1/48th per month Monthly vesting after first anniversary

RSU vesting period 3 years RSUs vest annually over three-year period

Annual RSU vesting rate One-third per year RSUs vest on each anniversary of grant date

Market Reality Check

Price: $3.81 Vol: Volume 146,753 vs 20-day ...

low vol

$3.81 Last Close

Volume Volume 146,753 vs 20-day average 342,141, indicating below-typical trading activity. low

Technical Price $4.20 is trading above the 200-day MA of $3.36, reflecting a pre-existing uptrend.

Peers on Argus

RPID gained 2.94% while peers showed mixed moves (e.g., OWLT -9.04%, PROF +1.26%...

RPID gained 2.94% while peers showed mixed moves (e.g., OWLT -9.04%, PROF +1.26%, RCEL -4.48%), suggesting stock-specific dynamics rather than a unified sector move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Prelim 2025 revenue	Positive	-1.0%	Record preliminary Q4 and full-year 2025 revenue update.
Jan 07	Conference appearance	Neutral	-1.2%	Announcement of presentation at J.P. Morgan Healthcare Conference.
Nov 18	Growth capital funding	Positive	+5.3%	$45M growth capital commitment to scale Growth Direct platform.
Nov 07	Q3 2025 earnings	Positive	+12.7%	Q3 2025 results with raised full-year revenue and placement guidance.
Oct 30	Conference participation	Neutral	+1.4%	Participation in Stifel 2025 Healthcare Conference with webcast access.

Pattern Detected

Recent clearly positive business updates (financing, raised guidance) generally saw aligned positive moves, with one divergence on preliminary record revenue.

Recent Company History

Over the last few months, Rapid Micro Biosystems reported several notable milestones. On Nov 7, 2025, it posted Q3 2025 results with raised full‑year revenue guidance and the largest multi‑system order, followed by a 12.73% gain. A $45M growth capital commitment reported on Nov 18, 2025 coincided with a 5.31% rise. The company then highlighted conference participation in late 2025 and early 2026. On Jan 13, 2026, record preliminary Q4 and full‑year 2025 revenue was followed by a modest -0.98% reaction.

Market Pulse Summary

This announcement details inducement equity awards—205,000 RSUs and 168,000 options at a $4.19 exerc...

Analysis

This announcement details inducement equity awards—205,000 RSUs and 168,000 options at a $4.19 exercise price—granted under Nasdaq Listing Rule 5635(c)(4) to three new employees. It follows a period highlighted by record 2025 revenue metrics, a $45M growth capital commitment, and raised guidance. Investors may track how ongoing equity-based compensation, alongside recently reported insider and shareholder sales, interacts with the company’s growth trajectory and capital deployment plans.

Key Terms

restricted stock units, non-qualified stock options, exercise price, nasdaq listing rule 5635(c)(4)

4 terms

restricted stock units financial

"announced the grants on February 2, 2026, of an aggregate of 205,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-qualified stock options financial

"and non-qualified stock options to purchase an aggregate of 168,000 shares of Common Stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"The Options have an exercise price of $4.19 per share, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on February 2, 2026, of an aggregate of 205,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) and non-qualified stock options to purchase an aggregate of 168,000 shares of Common Stock (the “Options”), all as a material inducement to employment for three new employees. All such equity awards were made under the Company’s Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.

The Options have an exercise price of $4.19 per share, which is equal to the closing price of Common Stock on their grant date. Twenty-five percent (25%) of Options will vest and become exercisable on the first anniversary of their grant date, and 1/48th of Options will vest and become exercisable each month thereafter, in each case, subject to such employee's continued employment on each vesting date.

The RSUs will vest annually over a three-year period, with one-third of the RSUs vesting on each anniversary of their respective grant dates, subject to such employee's continued employment on each vesting date.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

About Rapid Micro Biosystems

Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

FAQ

What equity awards did Rapid Micro Biosystems (RPID) grant on February 2, 2026?

The company granted 205,000 restricted stock units and 168,000 stock options as inducement awards. According to Rapid Micro Biosystems, these awards were made under the Inducement Plan and approved by a majority of independent directors.

What is the exercise price and vesting schedule for the RPID options granted February 2, 2026?

The options have a $4.19 exercise price, equal to the grant-date closing price. According to Rapid Micro Biosystems, 25% vest after one year, then 1/48th vests monthly thereafter, subject to continued employment.

How do the 205,000 RSUs granted by RPID vest for the new employees?

The RSUs vest annually over three years, with one-third vesting on each anniversary. According to Rapid Micro Biosystems, vesting is contingent on the employee's continued employment on each vesting date.

Why were inducement awards used for the new hires at Rapid Micro Biosystems (RPID)?

Inducement awards incentivize new hires who were not previously employees or returned after non-employment. According to Rapid Micro Biosystems, the Inducement Plan is used pursuant to Nasdaq Rule 5635(c)(4) for such hires.

Were the RPID inducement awards approved in compliance with Nasdaq rules on February 2, 2026?

Yes, the awards were approved by a majority of independent directors in line with Nasdaq Listing Rule 5635(c)(4). According to Rapid Micro Biosystems, the grants were made under the company’s Inducement Plan and related award agreements.